deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   3 Trials   3 Trials   90 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
deudextromethorphan/quinidine ultra-low dose (AVP-786) / Otsuka
2020-000798-26: A study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type.

Not yet recruiting
3
750
Europe, RoW
deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q], AVP-786-18, AVP-786-42.63, Capsule, hard
Otsuka Pharmaceutical Development & Commercialization, Inc., Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.Avanir Pharmaceuticals, Inc.
Agitation in patients with dementia of the Alzheimer’s type, Agitation due to Alzheimer, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03393520 / 2017-001339-38: Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Completed
3
601
Europe, US, RoW
Placebo, AVP-786
Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type
11/23
12/23
NCT04408755: Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Active, not recruiting
3
183
Europe, US, RoW
AVP-786, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type
12/25
03/26
NCT04464564 / 2020-000799-39: Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

Active, not recruiting
3
241
Europe, Canada, US, RoW
AVP-786, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation in Patients with Dementia of the Alzheimer's Type
08/26
11/26
NCT02446132 / 2017-002455-29: Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Active, not recruiting
3
1197
Europe, Canada, US, RoW
AVP-786
Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type
01/25
01/25
NCT03896945: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Terminated
2/3
136
Europe, US
Placebo, AVP-786
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
05/23
05/23
2021-001352-33: A clinical trial to assess the efficacy, safety, and tolerability of AVP-786 versus placebo for the treatment of negative symptoms of schizophrenia

Not yet recruiting
2/3
370
Europe
Deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q], AVP-786, Capsule, hard
Otsuka Pharmaceutical Development & Commercialization, Inc., Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc, Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc.
Negative symptoms of schizophrenia, Negative symptoms of schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 

Download Options